Research
Hormonal
Circadian misalignment between endogenous rhythms and exogenous sleep schedules causes Shift Work Disorder (SWD) and Jet Lag Disorder (JLD), characterized by sleep disturbance and impairment.
If you suffer from shift work or jet lag, the root cause is likely a mismatch between your internal body clock and your external schedule. Diagnosis requires documenting this misalignment, often using sleep logs or actigraphy for at least seven days. Treatment focuses on realigning the clock through scheduled sleep, timed light exposure, or melatonin.
WeakSupportsHIGH confidence
The essential feature of CRSDs is a persistent or recurrent pattern of sleep disturbance due primarily to alterations in the circadian timekeeping system or a misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep.
Why this rating
Based on ICSD-2 diagnostic criteria and extensive literature review.
Source
Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders
Robert L. Sack et al. · SLEEP · 2007
DOI 10.1093/sleep/30.11.1460
narrative_reviewCited 643×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Blue wavelength light is the most efficient stimulus for shifting the circadian system and suppressing melatonin due to its sensitivity in non-rod, non-cone photoreceptors.Limited
- Dim Light Melatonin Onset (DLMO) is a more stable and accurate marker of circadian phase than Core Body Temperature (CBT) because it is less susceptible to masking effects.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →